Q-omics provides the consensus-scored MIR5580 profile across patient tissues and cancer cell-line models. MIR5580 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, MIR5580 is differentially expressed in 1, with the highest sampling consensus in KIRC. Additionally, MIR5580 RNA expression shows 4,681 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight STAD, and KIRC as cancer lineages where MIR5580 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR5580 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR5580 survival associations across molecular data types. MIR5580 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR5580 RNA expression–survival associations across cancer types. High MIR5580 expression shows unfavorable associations in THYM, LUAD, LIHC and UCS, but favorable associations in STAD and LGG. The STAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for MIR5580 RNA expression.
This table summarizes MIR5580 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR5580. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR5580 shows lower tumor expression in KIRC. The KIRC box plot shows higher MIR5580 RNA expression in normal versus tumor tissue (log2 FC = −0.088, t-test p = .028).
This table shows molecular features associated with MIR5580 in patient tissues and cancer cell lines. In patient samples, MIR5580 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
